Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ryosuke Ushijima is active.

Publication


Featured researches published by Ryosuke Ushijima.


Tetrahedron | 1998

An efficient synthesis of the side chain intermediate of BO-2502A, a new 1β-methyl carbapenem, via diastereoselective lactamization as a key step

Norikazu Ohtake; Yasuyuki Imai; Ryosuke Ushijima

Abstract The BO-2502A side chain intermediate 3 was prepared via the diastereoselective lactamization of the in situ prepared amino diacid anhydride 14 as a key step. The diastereoselectivity of this step was found to be 53:1 (96% de).


Tetrahedron-asymmetry | 1997

DIASTEREOSELECTIVE SYNTHESIS OF THE KEY INTERMEDIATE OF THE BO-2727 SIDE CHAIN

Norikazu Ohtake; Hideki Jona; Shigemitsu Okada; Osamu Okamoto; Yasuyuki Imai; Ryosuke Ushijima; Susumu Nakagawa

Abstract The key intermediate of the BO-2727 side chain 3 was prepared diastereoselectively by two alternative methods: via the aldol reaction of (2S,4R)-N-Boc- tert -butyldimethylsilyloxyprolinal 5 with in-situ -generated ketene acetal 9 in the presence of TiCl 4 (95% de) and via the catalytic hydrogenation of β-keto amide 6i using (S)-BINAP-Ru as a catalyst (98% de).


Tetrahedron Letters | 1997

An efficient asymmetric synthesis of the mercaptopyrrolidine side chain of an important β-methyl carbapenem antibiotic

Joseph D. Armstrong; Jennifer L. Keller; Joseph J. Lynch; T. Liu; Frederick W. Hartner; Norikazu Ohtake; Shigemitsu Okada; Yasuyuki Imai; Osamu Okamoto; Ryosuke Ushijima; Susumu Nakagawa; Ralph P. Volante

Abstract An efficient asymmetric synthesis of the mercaptopyrrolidine side chain 2 1s described. The β-ketoester 4 is hydrogenated diastereoselectively to give the (R)-β-hydroxyester 5. The remaining functional groups are installed via a thiol Mitsunobu reaction and a reduction of a secondary amide to produce 2 in 34% overall yield from BOC-L-trans-4-hydroxyproline methylester 3 (Scheme 1).


Bioorganic & Medicinal Chemistry Letters | 1997

Novel dithiocarbamate carbapenems1 with anti-MRSA activity

Norikazu Ohtake; Hideaki Imamura; Hideo Kiyonaga; Hideki Jona; Masayuki Ogawa; Shigemitsu Okada; Aya Shimizu; Minoru Moriya; Hiroki Sato; Yushin Tominaga; Koji Yamada; Masato Nakano; Ryosuke Ushijima; Susumu Nakagawa

Abstract A new series of carbapenems, in which disubstituted-aminothiocarbonylthio moiety, directly attached to the C-2 position, were prepared and evaluated for their antibacterial potency. These analogs showed potent activity against high-level MRSA. Among them, 9e and 9i were found to exhibit good in vivo efficacy comparable to that of vancomycin, for mouse septicemia model with high-level MRSA.


Archive | 1988

Cephalosporin derivatives, processes for their preparation and antibacterial agents

Susumu Nakagawa; Norikazu Otake; Ryosuke Ushijima


Bioorganic & Medicinal Chemistry | 1998

Novel dithiocarbamate carbapenems with anti-MRSA activity

Norikazu Ohtake; Hideaki Imamura; Hideki Jona; Hideo Kiyonaga; Aya Shimizu; Minoru Moriya; Hiroki Sato; Masato Nakano; Ryosuke Ushijima; Susumu Nakagawa


Bioorganic & Medicinal Chemistry Letters | 2000

Structure–activity relationships of trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems. Part 1: J-111,347 and related compounds

Hideaki Imamura; Norikazu Ohtake; Aya Shimizu; Hideki Jona; Hiroki Sato; Rie Nagano; Ryosuke Ushijima; Koji Yamada; Terutaka Hashizume; Hajime Morishima


Archive | 1985

3-Isoquinoliniomethyl cephalosporin derivatives

Susumu Nakagawa; Ryosuke Ushijima; Eiichi Mano; Norikazu Ban; Minoru Sanada


Archive | 1983

2-Oxo-1-azetidinesulfonic acid derivatives, process for production thereof, and use thereof

Susumu Nakagawa; Fumio Nakano; Ryosuke Ushijima; Ikuo Iwatsuki; Shuichi Iwadare


Archive | 1990

2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives

Susumu Nakagawa; Koji Yamada; Ryosuke Ushijima

Collaboration


Dive into the Ryosuke Ushijima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Norikazu Ohtake

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge